Duopharma Announces Bonus Issue to Shareholders

Kuala Lumpur, February 27 2018 – CCM Duopharma Biotech Berhad (Duopharma) has proposed a bonus issue of up to 371,945,333 new ordinary shares on the basis of four (04) bonus shares for every three (03) existing shares, reflecting the company’s stronger fundamentals after it completed its demerger exercise earlier this year.

CCMD Sets to Make its Foray into Hepatitis Treatment

Kuala Lumpur – CCM Duopharma Biotech Berhad (CCMD) has entered into a collaboration with Natco Pharma Ltd of India to commercialise a range of Hepatitis C products in Malaysia to improve access and affordability for patients who currently have to fork out large sums of money for treatment in the country.

Beating the Odds at Autism CHAMPS’ “Every Child is a Champion” Campaign Raises RM50,000 in Support of NASSOM

Kuala Lumpur – Once considered rare, autism is now on the rise and approximately 67 million worldwide live with autism. According to the Malaysian Department of Social Welfare, there are close to 13,000 individuals in Malaysia who are registered as autistic in 2014. Meanwhile, the Malaysian Ministry of Health reported that autism cases in the country are on the rise every year, emphasising the importance of early treatment to improve a child’s development.

Recognising Champions in Autistic Children CHAMPS and NASOM Partner to Boost Awareness

Kuala Lumpur – Many champions among us often go unnoticed because their gifts and talents come in different forms that we fail to recognise. Children with autism are the unsung heroes, who are more often misunderstood than celebrated.

CCM Duopharma Partners India’s Natco and Biocon to Offer Affordable Treatment in Malaysia

New Delhi, India – Malaysia’s largest generic pharmaceutical manufacturer, CCM Duopharma Biotech Berhad (CCMD), a subsidiary of Chemical Company of Malaysia Berhad (CCM) has entered into a strategic alliance with India’s Natco Pharma Limited (Natco) and Biocon Limited (Biocon) to offer affordable cancer and insulin therapies in Malaysia.

CCM Duopharma Registers Double-Digit Top Line Growth in FY 2016

Kuala Lumpur – CCM Duopharma Biotech Berhad (CCMD), Malaysia’s largest pharmaceutical manufacturer registered a 16 per cent increase in revenue to RM312.94 million for the financialyear ended 31 December 2016 (FY 2016) from RM269.79 million in the previous year.

CCM Duopharma Biotech Berhad Through its Subsidiary CCMP Secures LOA from Ministry of Health for RM300 Million Insulin Contract

Kuala Lumpur – CCM Pharmaceuticals Sdn Bhd (CCMP), a subsidiary of CCM Duopharma Biotech Berhad (CCMD), and Biocon Sdn Bhd (a subsidiary of Biocon Ltd) have been awarded a Letter of Award (LOA) by the Ministry of Health (MOH) to supply Human Insulin to all government hospitals and clinics valued at RM300 million for three years until December 1, 2019.